Flossonics

Flosonics Medical develops and commercializes non-invasive, wearable sensors for the clinical management of critically ill patients. The company's business model is centered on selling its flagship product to hospitals and healthcare systems for use in settings like the ICU, emergency department, and operating rooms. It serves a B2B2C market, providing tools for clinicians to improve patient care. Having raised a total of $39M over 5 funding rounds, the venture-backed company is in a scale-up phase.

The company's core product is the FloPatch, described as the world's first wireless, wearable Doppler ultrasound system. This single-use, adhesive sensor is applied to a patient's neck to monitor blood flow in the carotid artery. The device uses continuous-wave Doppler ultrasound to provide real-time hemodynamic assessments, sending data via Bluetooth to a mobile app. The app displays key metrics such as Corrected Flow Time (FTc) and Velocity Time Integral (VTI), which help clinicians make informed decisions about fluid resuscitation. The key benefit of FloPatch is that it offers a hands-free, non-invasive, and rapid method for assessing a patient's fluid responsiveness, a critical factor in managing conditions like sepsis and septic shock. The technology has received regulatory clearance from both the FDA and Health Canada.